Recurrent chromosome 12p deletions are associated with distinct tumor types and suggest the presence of a tumor suppressor gene (TSG). Previously, we mapped an EST with similarity to a protein tyrosine phosphatase to the minimally deleted region for all these neoplasms. The corresponding gene, DUSP16/MKP-7, was recently shown to code for a mitogen-activated protein kinase phosphatase, suggestive for a function as tumor suppressor. Overexpression of DUSP16 in BCR-ABL-transformed Rat-1 fibroblasts reduces their transforming capacity in vitro and in vivo via downregulation of BCR-ABL-induced JNK activation. A role for DUSP16 as a regulator of JNK signaling was further demonstrated via overexpression in Ba/F3 cells, which increased their antiapoptosis. However, no inactivating mutations could be detected in leukemia patients hemizygous for DUSP16, and the effect of hemizygosity on DUSP16 expression level could not be assessed due to the variability of DUSP16 transcript levels observed in leukaemia cell lines and in patients. Taken together, the functional data point to a context-dependent role for DUSP16 on cell transformation and apoptosis, reflecting the dual role of JNK, and therefore suggest that DUSP16 might be haploinsufficient for tumor suppression.
Introduction
Frequent deletions of the short arm of chromosome 12 in tumors suggest the presence of a tumor suppressor gene (TSG) . Fluorescent in situ hybridization (FISH) and loss of heterozygosity (LOH) studies showed that the commonly deleted region on chromosome 12p12-13 in leukemia is flanked by ETV6 at the telomeric side and D12S358 at the centromeric side (Sato et al., 1995; Wlodarska et al., 1996; Baens et al., 1999) . The chromosome 12p deletions reported in a number of solid tumors also include part of the ETV6-CDKN1B interval (Spirin et al., 1996; Takeuchi et al., 1996; Hatta et al., 1997; Kibel et al., 2000; Latil et al., 2001) .
Several genes located in this critical region have already been evaluated as candidate TSGs. ETV6 (TEL) is involved in various chromosomal translocations, resulting in the formation of oncogenic fusion proteins. The fusion of ETV6 to the CBFA2 gene on chromosome 21 in childhood ALL is frequently associated with a deletion of the nontranslocated ETV6 allele as a secondary event, suggesting further proliferative advantage to the leukemic cells (Raynaud et al., 1996; Romana et al., 1996) . In other malignancies however, a tumor suppressor role for ETV6 is doubtful as biallelic inactivation is rare (Stegmaier et al., 1996; Hatta et al., 1997) . Biallelic inactivation of LRP6, present in the critical region, also seems to be uncommon in leukemia (Baens et al., 1999) , and the discovery of its essential role in transducing Wnt signals to b-catenin stabilization and cell proliferation further questions its role as TSG (Pinson et al., 2000; Tamai et al., 2000) . Likewise, no inactivating mutations of the proapoptotic protein BCL-G were observed in tumor samples (Guo et al., 2001) .
So far, the best candidate for the chromosome 12p TSG is CDKN1B (p27
KIP1
), a member of the family of cyclin-dependent kinase inhibitors, including CDKN2A (p16) and CDKN2B (p15), frequently inactivated in a variety of cancers. But again, although hemizygous CDKN1B deletions are often observed in multiple tumors, biallelic inactivation appears to be the exception (reviewed in Philipp-Staheli et al., 2001) . Nevertheless, reduced expression of CDKN1B is frequently found in human carcinomas and correlates with poor patient survival (reviewed in Slingerland and Pagano, 2000) , which is consistent with the enhanced tumor development observed in Cdkn1b þ /À mice (Fero et al., 1998) and is in line with the hypothesis that CDKN1B is haploinsufficient for tumor suppression.
However, CDKN1B is not always included in the chromosome 12p deletion, indicating that in these tumors (an)other gene(s) might be the target. Since LRP6, BCL-G and ETV6 do not fulfill the classical criteria for a TSG, we evaluated DUSP16 (recently described as MKP-7) that resides in the critical region on chromosome 12p. No biallelic inactivation of DUSP16 was observed in leukemia patients and variable DUSP16 transcript levels in leukemia cell lines and patient material precluded the evaluation of a potentially reduced DUSP16 expression in leukemogenesis. Ectopic expression of DUSP16 in BCR-ABL-transformed Rat-1 cells, however, clearly suppressed cell growth and transformation in vitro and in vivo, which depends completely on its function as an MAPK phosphatase. These observations lead us to hypothesize that DUSP16 might be haploinsufficient for tumor suppression.
Results

Chromosome 12p deletions in hematological and solid tumors
Several FISH and LOH studies have delineated a commonly deleted region on chromosome 12p12-13 and are summarized in Figure 1 . In leukemia, this region is flanked by ETV6 at the telomeric side and D12S358 at the centromeric side (Sato et al., 1995; Baens et al., 1999) . In prostate cancer, this region is bordered by D12S391 (telomeric) and D12S358 (centromeric) (Kibel et al., 2000) , whereas in non-small-cell lung cancer it extends from D12S358 (telomeric) to D12S320 (centromeric) . Therefore, if the same TSG is involved in the development of all these tumors, the critical region for it is spanning D12S358. Alternatively, two or more TSGs might be located at either side of this locus.
The presence of a TSG near D12S358 is also supported by a homozygous 12p deletion observed in a T-PLL sample (Hetet et al., 2000) . This homozygous deletion is bordered at the telomeric side by b312C2T7 and includes D12S358 and CDKN1B (see Figure 1 ). Yet, another homozygous deletion observed in prostate cancer includes D12S1697, ETV6, D12S391 and CDKN1B, but surprisingly D12S358 is retained, indicating that the deletion might be the result of a rather complex rearrangement (Kibel et al., 1999) .
Identification and cloning of DUSP16
In a previous study, we generated a physical and transcript map of the region between ETV6 and CDKN1B (Baens et al., 1999) . One of the ESTs located at the D12S358 locus, cds4ba2 (Accession no. AF090130), showed similarity with protein tyrosine phosphatases. We used this EST as a probe to screen a bone marrow cDNA library (Clontech), which yielded a cDNA of 3.6 kb (Accession no. AF506796). The transcript has an open reading frame (ORF) of 1995 nt, which is identical to the recently published MAPK phosphatase MKP-7/DUSP16 (Masuda et al., 2001; Tanoue et al., 2001) . Two transcripts of 4 and 6 kb were detected for DUSP16 in all tissues present on a human multiple tissue Northern blot (Clontech) (Figure 2a) . Analysis of an RNA master blot (Clontech) confirmed the ubiquitous expression pattern of DUSP16 (Figure 2b ).
Mutation and expression analysis of DUSP16 in leukemia samples
In order to evaluate mutational inactivation of DUSP16 in leukemia patients with hemizygous 12p deletions, we first determined its genomic structure. Sequence analysis of subclones of cosmid 112H1 and BAC 267E23 (see Figure 1 ), detected upon colony hybridization with the bone marrow DUSP16 cDNA as a probe, revealed that DUSP16 consists of seven exons ( Table 1 ). The first exon of DUSP16 is associated with a CpG island (Accession no. Z66325) and the gene has a centromereto-telomere orientation with D12S358 located in intron 5.
To identify mutations in the coding region of DUSP16, we designed six sets of primers that allow the amplification of the complete coding region using genomic DNA of the patients as template, and used the amplification products, after cleavage with the selected restriction endonucleases, for single-strand conformation analysis (SSCA). Analysis of 22 leukemia patients (Table 2) , 17 of them with hemizygous chromosome 12p deletions, resulted in the identification of four base substitutions; however, none of them altered the aminoacid composition (Table 3) . A coding polymorphism giving rise to a deletion of three amino acids (residues 364-366, ProSerVal) was discovered in exon 7. In the majority of Caucasians, the nonanucleotide encoding these three amino acids (CC AGC GTG C) is repeated three times. However, 6% of the alleles contain only two Figure 1 Transcript and deletion map of chromosome region 12p12-13. The STSs and known genes are shown at the top (according to Baens et al. (1999) and Montpetit et al. (2002) . The lower section gives an overview of LOH and FISH studies of tumors with chromosome 12p deletions. Gray rectangles, commonly deleted region for each study; black lines, homozygous deletions; gray circle, the STS or FISH probe is hemizygously deleted; black circle, homozygously deleted STS; white circle, both alleles of the marker are retained. (1) (Sato et al., 1995; Wlodarska et al., 1996; Baens et al., 1999) ; (2) (Hetet et al., 2000) ; (3) ; (4) (Hatta et al., 1997) ; (5) (Spirin et al., 1996) ; (6) (Kibel et al., 1998 (Kibel et al., , 2000 ; (7) Hetet et al., 2000) ; (8) (Kibel et al., 1999) Tumor suppression by the MAPK phosphatase DUSP16/MKP-7 I Hoornaert et al nonanucleotides (DUSP16D3). Also no de novo methylation of the CpG island of DUSP16 was observed (data not shown).
Real-time quantitative PCR was performed to assess DUSP16 transcript levels in leukemia cell lines and patients with or without a hemizygous 12p deletion, using UBC (Ubiquitin C) as internal reference. The slope of the fitted line for the mean DC t value at different mRNA concentrations was À0.032, indicating the same amplification efficiency for both reactions. DUSP16 transcript levels were first analysed in a series of leukemia samples with or without 12p deletion. As shown in Figure 3a , the mean DC t for DUSP16 compared to UBC showed a difference of 0.4 C t values, a value that corresponds to B25% reduction in DUSP16 transcript level for the del(12p) population. However, this difference is statistically not significant: s.d.'s for the DC t values were 1.21 and 0.71 for the deletion 12p and control population, respectively. The same variability in DUSP16 transcript levels was observed in B-ALL-derived cell lines (REH, ACC 42 and BALL-1) with a s.d. of 1.75 ( Figure 3b ). The DC t value for GRANTA 517, a B-cell lymphoma cell line with del (12), is 8.44, which means higher DUSP16 transcript levels than in REH and BALL-1 and lower than in ACC 42. The differences in genetic background in these cell lines and also in the leukemia patients are most likely the cause for the heterogeneity in DC t values, which makes it difficult to assess the effect of DUSP16 hemizygosity due to the lack of proper (matched) control samples.
Overexpression of DUSP16 inhibits JNK activation
Previous studies indicated that DUSP16 is a dualspecificity phosphatase (DUSP) that preferentially inactivates JNK and in a lesser extent p38 MAPK (Masuda et al., 2001) . Activation of the JNK pathway plays an essential role in the transformation by the BCR-ABL oncogene (Raitano et al., 1995; Cortez et al., 1997) . Therefore, BCR-ABL-transformed Rat-1 cells were used as a model system to evaluate a role for Tumor suppression by the MAPK phosphatase DUSP16/MKP-7 I Hoornaert et al DUSP16 as a negative regulator of JNK signaling and associated cellular transformation. Parental Rat-1 fibroblasts and BCR-ABL.Rat-1 cells were transduced with empty vector or with Myctagged constructs for wild-type DUSP16, containing three (DUSP16) or two nonanucleotide repeats (DUSP16D3), and a phosphatase inactive mutant with the catalytic cysteine (AA 244) substituted by serine (DUSP16CS). Immunoblotting showed a similar expression level for the different DUSP16 constructs in all the generated cell lines (Figure 4a) . To assess the effect of overexpression of DUSP16 on the phosphorylation of JNK and p38, cells were stimulated with anisomycin, an activator of JNK and p38 signaling. As shown in Figure 3b , overexpressed DUSP16 significantly reduced the endogenous level of active, phosphorylated JNK compared to vector-transduced cells. The level of phosphorylated p38 MAPK was not altered in vector or DUSP16-transduced BCR-ABL.Rat1 cells (Figure 4b ), which is consistent with a previous report showing substrate specificity of DUSP16 for JNK (Masuda et al., 2001 ).
Overexpression of DUSP16 reduces BCR-ABL-induced transformation
To evaluate the functional consequences of JNK inactivation by overexpression of DUSP16, we established first growth curves for the different BCR-ABL.Rat-1 cell lines. Figure 5a clearly indicates a significant growth reduction conferred by wild-type DUSP16 or DUSP16D3. Accordingly, the doubling time for BCR-ABL.Rat-1 cells expressing DUSP16 or DUSP16D3 was increased by 47% compared to vectortransduced cells, an effect that was also evident in wild-type Rat-1 cells (35%, results not shown). BCR-ABL.Rat-1 cells expressing phosphatase-inactive DUSP16CS also showed a small reduction in their growth rate; however, the difference in doubling time compared to DUSP16-expressing cells was significant (Wlodarska et al., 1996) . e Patient sample number in a previous study (Baens et al., 1999) . Tumor suppression by the MAPK phosphatase DUSP16/MKP-7 I Hoornaert et al and must be ascribed to its inability to inactivate JNK. Next we evaluated whether reduced JNK phosphorylation altered the anchorage independency of BCR-ABL.Rat-1 cells (Lugo and Witte, 1989) . Overexpression of DUSP16(D3) indeed reduced the formation of large colonies (diameter >0.3 mm) by approximately 75% compared to vector-transduced cells, although a considerable increase in the total number of macroscopically visible colonies was obtained (Figure 5b) . BCR-ABL.Rat-1 cells expressing DUSP16CS displayed similar colony formation properties as vector-transduced cells. Furthermore, Lugo and Witte (1989) reported that BCR-ABL.Rat-1 cells are less adherent to plastic substrates compared to normal Rat-1 cells. We observed that overexpression of DUSP16(D3) in BCR-ABL.Rat-1 cells caused a reversion of this phenotype, which was unaffected by DUSP16CS. The latter showed a progressive detachment from the plastic substrate, similar to vector-transduced cells (Figure 5c ).
Finally, the tumorigenicity of vector-transduced and DUSP16-transduced BCR-ABL.Rat-1 cells was investigated in vivo by subcutaneous injection of 10 6 cells (in exponential growth phase) into the right flank of nude mice. All mice had clearly visible tumors after 3 weeks, but for cells overexpressing DUSP16 the average tumor weight was reduced by 60% compared to vectortransduced cells (Figure 5d ).
Overexpression of DUSP16 in BA/F3 cells
Signals relayed by JNK regulate a range of cellular processes including cell proliferation, tumorigenesis, apoptosis and embryonic development. To investigate a role of DUSP16 in apoptosis, we expressed DUSP16 in interleukin 3 (IL3)-dependent Ba/F3 cells (Figure 6a) . At 24 h after IL3 withdrawal, the degree of apoptosis of vector-, DUSP16-and BCL2-transduced cells was determined via annexin V staining and measurement of caspase-3 activity in cell lysates. Although not as potent as ectopic BCL2, overexpression of DUSP16 reduced caspase-3 activity with 42% and the percentage of apoptotic cells (annexin V high , propidium iodide negative) with 24% compared to vector-transduced cells (Figure 6b ).
Discussion
Here, we provide evidence that DUSP16, located in the candidate region for a TSG on chromosome 12p, preferentially acts as a JNK MAPK phosphatase and has tumor suppressing potential. DUSP16 overexpression reduces the growth of Rat-1 cells in reduced serum conditions and suppresses the transforming capacity of BCR-ABL-transformed Rat-1 cells in vitro and in vivo. In addition, DUSP16 inhibits apoptosis induced in Ba/F3 cells by IL3 withdrawal.
MAPKs are important signaling molecules, which can be classified in at least three distinct groups: ERK, JNK and p38 MAPKs. The role of each MAPK is cell type- (Furukawa et al., 1998) . This hypothesis was strengthened by the observation that overexpression of DUSP6 induces cell cycle arrest and apoptosis in tumor cells in which the ERK pathway is constitutively activated (Hoshino et al., 2001) . DUSP16 is located in a candidate TSG region on chromosome 12p12-13. No inactivating mutations of DUSP16 were identified in 17 leukemia patients with hemizygous chromosome 12p deletions. Also, no de novo methylation of the CpG island of DUSP16 was observed in five of these samples, suggesting that methylation of this CpG island is not a common mechanism for inactivation of the second allele. Analysis of a number of leukemia patients with deletion of one allele of DUSP16, confirmed by FISH analysis (data not shown), showed slightly reduced DUSP16 transcript levels compared to the control population, consisting of leukemia samples without del(12p). These results however were statistically not significant due to the variability of DUSP16 transcript levels observed in both populations; therefore the generation Dusp16 þ /À mice might be required to evaluate a possible reduction in transcript level.
However, the location of DUSP16 in a region, frequently deleted in tumors, and its function as MAPK inactivator hint towards an ability to suppress cellular transformation. Coexpression experiments showed that DUSP16 preferentially inactivates JNK and to a lesser extent p38 MAPKs (Masuda et al., 2001) . Their suggestion that JNK probably works as a JNK specific Tumor suppression by the MAPK phosphatase DUSP16/MKP-7 I Hoornaert et al phosphatase in vivo is supported by our results that demonstrate that overexpression of DUSP16 reduces the phosphorylation of endogenous JNK but not p38. It has been reported that the JNK pathway is constitutively activated in several tumor cell lines (Bost et al., 1997; Antonyak et al., 1998) , and that its inhibition sometimes can reverse the phenotype (Huang et al., 1999; Xiao and Lang, 2000) . Dominant-negative mutants of c-Jun, distal in the JNK signaling pathway, impair the transforming properties of BCR-ABL in fibroblasts and hematopoietic cells (Raitano et al., 1995) . Similarly, we show that overexpression of DUSP16 reduces BCR-ABL-induced transformation of Rat-1 cells, demonstrated by diminished colony formation in soft agar, reduced proliferation in low-serum conditions, increased adhesion to plastic substrates and decreased tumor formation in nude mice. The phosphatase activity of DUSP16 is indispensable for suppression of transformation, since DUSP16-CS does not alter the phenotype of BCR-ABL-transformed cells. Masuda et al. (2001) however reported that DUSP16-CS might act as a dominant-negative with respect to dephosphorylation, as increased levels of phosphorylated JNK were observed. Although we did not assess the phosphorylation status of JNK in DUSP16-CS-expressing BCR-ABL.Rat1 cells, DUSP16CS does not increase the transforming properties of BCR-ABL.Rat-1 cells. On the contrary, these cells showed a slight reduction in growth rate compared to vector-transduced cells, suggesting inhibition of JNK activity possibly through sterical hindrance.
Disruption of actin filaments and a decrease in focal adhesions are common features of oncogenic transformation (Pawlak and Helfman, 2001) . Reversal of the defect in adhesion of BCR-ABL.Rat-1 cells by the overexpression of DUSP16 suggests a contribution of the JNK pathway to this phenotype. Furthermore, we observed that DUSP16 overexpression reduces the number of large colonies in soft agar. But surprisingly, BCR-ABL.Rat-1 cells overexpressing DUSP16 showed a considerable increase in the total number of macroscopically visible colonies compared to the vector control. A similar reduction in the number of large colonies was observed when cells were plated 10-fold diluted, excluding serum depletion as the cause of their restricted growth (data not shown). This suggests that DUSP16 stimulates the initiation of colony formation in soft agar but subsequently prevents their further growth. This might be because in addition to its inhibiting effect on transformation, DUSP16 might have a survival or antiapoptotic effect in these conditions. It has been shown that depending on cell type and stimulus, JNK can have either a pro-or antiapoptotic property (Davis, 2000) and hence, DUSP16 as an inactivator of JNK might regulate both processes. We found that overexpression of DUSP16 confers antiapoptosis to Ba/F3 cells upon IL3 withdrawal. Whether this is due to reduced JNK and/or p38 activity needs further analysis. However, we observed that in the presence of IL3, overexpression of DUSP16 reduces the JNK activity (data not shown). Others described that overexpression of the mouse orthologue of DUSP8, M3/6, where gene product preferentially inactivates JNK (Muda et al., 1996) , has no effect on the viability of Ba/F3 cells after IL3 withdrawal (Smith et al., 1997) . This difference in outcome upon overexpression of the two MKPs may reflect a different substrate specificity by which distinct JNK isoforms and/or other MAPK pathways are inactivated, or may be the result of different subcellular localizations of DUSP8, DUSP16 and MAPKs in these Ba/F3 cells.
In conclusion, we showed that DUSP16 as JNK phosphatase can suppress cell growth and transformation of BCR-ABL.Rat-1 cells in vitro and in vivo. However, no biallelic inactivation of DUSP16 was observed in leukemia patients with a deletion of chromosome 12p and experimental variability prevents the statistically relevant measurement of reduced DUSP16 transcript levels. Nevertheless, based on the functional data, we hypothesize that DUSP16 could be haploinsufficient for tumor suppression triggered by a reduced expression and diminished negative regulation of the JNK pathway. 
Materials and methods
DNA samples and mutation analysis of DUSP16 Genomic DNA from 22 blood samples of leukemia patients assembled at the Center for Human Genetics (Leuven, Belgium) was extracted by standard methods. The leukemia samples were analysed for mutations in DUSP16 by SSCA of PCR products digested with selected restriction endonuclease (Liu and Sommer, 1995 Quantitative real-time PCR mRNA expression levels of DUSP16 and an internal control gene (UBC) were quantified using real-time PCR analysis on an ABI Prism 7700 sequence detection system (PE Applied Biosystems). First-strand cDNA was synthesized from 2 mg of total RNA using random hexamers and SuperscriptII reverse transcriptase according to the manufacturer's instructions (Life technologies) and subsequently diluted 1:20 with nuclease-free water. Amplification of DUSP16 PCR products was detected using a dual-fluorescent nonextendable probe (5 0 -FAM-TCTTGGCTGCCAGCGAGATGTCC-TAMRA-3 0 ) with primers DUSP16-TMf (5 0 -CCCGAATTCTTCCCAAT CTTT-3 0 ) and DUSP16-TMr (5 0 -GCTGCATCAGCTCC TTGTTG-3 0 ). The SYBR Green I RT-PCR method was applied for amplification of UBC using primers UBC-TMf (5 0 -ATTTGGGTC1GCGGTTCTTG-3 0 ) with UBC-TMr (5 0 -TGCCTTGACATTCTCGATGGT-3 0 ). The quantitative real-time PCR was performed in a total reaction volume of 25 ml containing 1 Â amplification buffer (Eurogentec, Seraing, Belgium), 5 mM MgCl 2 , 200 mM of each dNTP (Amersham Pharmacia Biotech), 500 nM forward and reverse primer, 250 nM dual-labeled fluorogenic internal probe or SYBR Green (optimized concentration, recommended by the manufacturer, Eurogentec), 1.25 U AmpliTaq Gold DNA polymerase (Eurogentec) and 5 ml cDNA as template in Thermo-Fast 96-well PCR plates (ABgene, surrey, UK) sealed with optical adhesive covers (PE Applied Biosystems). Samples were heated for 10 min at 951C and amplified for 35 cycles of 15 s at 951C and 60 s at 601C. Since both PCRs performed with equal efficiencies, relative mRNA expression levels of DUSP16 can directly be normalized for input RNA against UBC expression. The target PCR C t value is normalized to the UBC PCR C t value by subtracting the UBC C t value from the DUSP16 PCR C t value, which gives the DC t value.
Construction of DUSP16 expression plasmids
The ORF of DUSP16 was amplified from spleen cDNA with the primers DUSP16-fl-F (5 0 GAGGACGGATCCTTGT CATGGCCCATGAG 3 0 ) and DUSP16-fl-R (5 0 TCTTT CGGGCCCGGAGACCTCAATGATTTCC 3 0 ). The amplification product was cloned into pGEM-T-easy (Promega), sequenced and subcloned into pcDNA3.1/Myc-HisA (Invitrogen). The inactive mutant of DUSP16, in which the catalytic Cys at position 244 was replaced by Ser (DUSP16CS), was generated by PCR-based mutagenesis. A shorter DUSP16 construct lacking three amino acids (residues 364-366) (DUSP16D3) was generated by subcloning a PCR fragment amplified from genomic DNA of an individual with this polymorphism into the normal DUSP16 cDNA. Retroviral pMSCV constructs expressing DUSP16, DUSP16CS, DUSP16D3 and BCL2 were constructed by subcloning the different cDNAs together with the Myc-tag from pcDNA3.1 into the pMSCV puromycin vector (kindly provided by Dr DG Gilliland, Harvard University, Boston, MA, USA).
Cell culture, virus production and transduction
Rat-1 and P210 BCR-ABL.Rat-1 cells (Lugo and Witte, 1989) (kindly provided by NK Tonks, Cold Spring Harbor Laboratory, NY, USA) were grown in DMEM-F12 (Life Technologies), supplemented with 10% fetal bovine serum (FBS) and 500 mg/ml G418 (BCR-ABL.Rat-1 cells). Ba/F3 cells (Palacios and Steinmetz, 1985) were grown in DMEM-F12 supplemented with 10% FBS and 10% conditioned medium from the IL3-producing cell line, WEHI-3B. Retroviral stocks and transductions were performed as described (Cools et al., 2002) . At 24 h after transduction, selection with puromycin was started. Drug-resistant populations were obtained after 5-12 days with 3 mg/ml puromycin for Rat-1 cells, 4.5 mg/ml for BCR-ABL-transformed Rat-1 fibroblasts and 2 mg/ml for Ba/F3 cells.
Growth in reduced serum
Rat-1 and BCR-ABL.Rat-1 cells transduced with the different constructs were plated at a density of, respectively, 10 4 and 2 Â 10 4 cells per 9.6 cm 2 well in DMEM-F12 supplemented with 3% newborn calf serum (NCS) (Life Technologies). The culture medium was refreshed every 3 days. The total cell number was determined at least every 2 days (Coulter counter). Doubling times were calculated during the exponential growth phase. Experiments were performed at least in double using independent transductions.
Anchorage-independent growth
After puromycin selection, 10 3 or 10 4 viable cells were plated in 0.35% agar in 10% FBS-containing medium per 9.6 cm 2 well. The cells were plated on top of a bottom layer with 0.6% agar in 10% FBS-containing medium. The plates were further treated as described (Lugo and Witte, 1989) . Two or three independent experiments were performed in triplicate.
Adhesion assay
After puromycin selection, 3 Â 10 5 cells were plated in a 9.6 cm 2 well in DMEM-F12 with 10% FBS. After 3 and 5 days, the medium was refreshed. After 1 week, the cells were fixed with 3% glutaraldehyde in PBS and stained with 1% crystal violet in PBS. This experiment was performed three times using independent transductions.
Apoptosis assays
Ba/F3 cells grown in DMEM-F12 supplemented with 10% FBS and 10% WEHI-3B-conditioned medium (as a source of IL-3) were collected in exponential growth phase, washed twice with PBS and 4 Â 10 5 cells/ml were cultured in DMEM-F12 with 10% FBS. At 24 h after IL3 withdrawal, 2-4 Â 10 6 cells were collected by centrifugation (180 g, 10 min, 41C), washed with PBS and resuspended in 150 mM NaCl, 50 mM Tris-HCl pH 7.5, 1% NP40 (v/v), 0.5% Na-deoxycholate, 1 mM EDTA. After lysis, the cell debris was removed by centrifugation (16 000 g, 5 min, 41C). For 100 mg of protein, the caspase-3 activity was measured in 100 mM NaCl, 50 mM HEPES, 10 mM dithiothreitol, 1 mM EDTA, 10% glycerol, 0.02% (w/v) CHAPS, supplemented with 0.4 mM Ac-DEVD-pNA (Alexis Biochemicals) as substrate. Release of pNA was monitored with a microplate reader (FluoStar Galaxy, BMG Labtechnologies) at 405 nm.
For annexin V staining, 4 Â 10 5 cells were collected by centrifugation. The percentage of apoptotic cells (annexin V high , propidium iodide negative) were determined using the Annexin V-EGFP Apoptosis Detection Kit (BioVision) and flow cytometry (FACScan, Becton Dickinson, San Jose, CA, USA).
